Answer: Narcolepsy due to Medical Condition
The Prader-Willi syndrome (PWS) is a genetic disorder in which genes on the paternal chromosome 15 are missing or unexpressed. The genes are "imprinted," meaning corresponding genes on the maternal chromosome 15 are not expressed. A minority of cases occur from maternal uniparental disomy (both of the 15 th chromosomes are maternal). PWS is characterized by short stature, hyperphagia, obesity, hypothalamic-pituitary dysfunction, and sleep disorders. Hypotonia and feeding difficulties are common in the neonatal period. In infancy, patients have a failure to thrive and developmental delay. Strabismus may also occur. Starting around age 2 to 4 years, PWS individuals exhibit hyperphagia and excessive weight gain, which can result in morbid obesity. Due to hypogonadotrophic hypogonadism they have delayed puberty. Abnormal growth hormone secretion results in short stature, a low bone density, and reduced muscle mass. The characteristic appearance of PWS patients includes a high narrow forehead, almond shaped eyes, down-turned lips, a prominent nasal bridge, and small hands and feet. Scoliosis is common (up to 80%). Intelligence is variable but is usually in the low normal to mild to moderately decreased range.
Patients with the PWS may have excessive daytime sleepiness from a number of sleep disorders including sleep apnea, narcolepsy, or as a manifestation the PWS itself. 1 Sleep related breathing disorders associated with PWS are common and include both obstructive and central apnea and hypoventilation. [2] [3] [4] [5] The frequency of obstructive apnea in studies of PWS patients varies widely (0-100%) and this likely represents patient selection. Risk factors for OSA in PWS patients other than obesity or tonsillar hypertrophy include facial dysmorphism, hypotonia, and sticky secretions. Of interest, one recent study 5 of a group of 53 PWS children with a relatively normal BMI (median 17.7 kg/m 2 ) found a median apnea + hypopnea index (AHI) of 5.4/hour with most events being central apneas.
Treatment of PWS patients with growth hormone (GH) can improve body composition (greater muscle mass and lower percentage fat) and increase height. 6 However, sudden death has been reported in a few patients in the first few months of growth hormone treatment. 6 The deaths often occurred during an upper respiratory tract infection and some of the patients were morbidly obese. Of note, one death was noted in a patient with a normal pretreatment sleep study. One theory is that GH treatment by increasing insulin-like growth factor (IGF) caused adenotonsillar hypertrophy with worsening of upper airway narrowing. Miller and coworkers 4 performed sleep studies in 25 PWS patients before and after 6 weeks of growth hormone treatment. All patients had both obstructive and central events before treatment. Sixteen patients had a lower apnea + hypopnea index (AHI) at 6 weeks, with improvement in both central and obstructive events in most patients. Six patients had a higher AHI after GH treatment, and those patients also developed tonsillar hypertrophy. Another study 5 found no change in the AHI at 6 months after GH treatment, although one patient died unexpectedly during an upper respiratory tract infection. A definite link between sleep apnea and sudden death in PWS following GH treatment has not been proven. However, those patients with morbid obesity, untreated obstructive sleep apnea, concurrent respiratory infections, or hypoventilation are probably not good candidates for GH treatment.
Excessive daytime sleepiness in patients with PWS can occur early in life and can cause significant problems for the patients. A short nocturnal REM latency and MSLT findings of a short sleep latency and two or more sleep onset REM periods have been reported in PWS patients without sleep apnea. 1 Such patients are considered to have narcolepsy due to a medical disorder also termed symptomatic or secondary narcolepsy. 7 Cataplexy has been reported in some patients with PWS 8 but a reliable history is often difficult to elicit. Some patients with PWS without sleep apnea also have daytime sleepiness but do not meet diagnostic criteria for narcolepsy. In these cases, sleepiness is likely a manifestation of the PWS itself.
Hypothalamic dysfunction might be suspected as the cause of daytime sleepiness in PWS given other manifestations of the disorder such as hyperphagia and growth hormone secretion dysfunction. Nevsimolva et al 9 studied 4 PWS patients without cataplexy (2 with excessive sleepiness) and found a reduced CSF level of hyopocretin 1 (about 60% of the control group level). However, Fronczek and coworkers 10 did not find a decrease in hypocretin neurons in PWS patients compared to age matched controls. Thus, some abnormality in the hypocretin system could be involved in the causation of daytime sleepiness of PWS. However, the exact nature of the dysfunction and the role of the hypocretin system in producing daytime sleepiness in PWS remain to be determined.
The current patient was not felt to have cataplexy. The nocturnal sleep study showed no evidence of sleep apnea, but the REM latency was significantly decreased. A MSLT was performed following the nocturnal sleep study. The MSLT findings included a mean sleep latency of 3.4 minutes (severe sleepiness) and REM sleep was present in 3 of the 5 naps. On the basis of these results the patient was diagnosed with narcolepsy due to a medical condition (PWS).
CLINICAL PEARLS
1. Patients with PWS frequently have obstructive sleep apnea, in part due to associated hyperphagia and obesity 2. Patients with PWS may also have central sleep apnea 3. PWS is one cause of narcolepsy due to a medical condition (ICSD-2) also known as symptomatic or secondary narcolepsy 4. PWS patients may exhibit daytime sleepiness in the absence of sleep apnea or narcolepsy, and this may be a manifestation of the disorder itself. 5. Growth hormone therapy may worsen obstructive sleep apnea in some patients with PWS. Sudden death has been reported following initiation of GH treatment in PWS. However, a definite link between sudden death and sleep apnea has not been proven.
